OverviewSuggest Edit

Personalis operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. 

TypePublic
Founded2011
HQMenlo Park, CA, US
Websitepersonalis.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Mar 2019)147
Revenue (FY, 2020)$78.6 M(+21%)
Share Price (Sept 2021)$21.4
Cybersecurity ratingBMore

Key People/Management at Personalis

John West

John West

Chief Executive Officer, Board Member
Richard Chen

Richard Chen

Chief Science Officer
Aaron Tachibana

Aaron Tachibana

Chief Financial Officer
Susan Moriconi

Susan Moriconi

Vice President of People and Chief Human Resources Officer
Carol J. Tillis

Carol J. Tillis

Vice President, Finance and Administration
Stephen Moore

Stephen Moore

General Counsel
Show more

Personalis Office Locations

Personalis has offices in Menlo Park and West Wickham
Menlo Park, CA, US (HQ)
1330 O'Brien Dr
West Wickham, GB
Squires House, 205A High Street
Show all (2)

Personalis Financials and Metrics

Personalis Revenue

Embed Graph
View revenue for all periods
Personalis's revenue was reported to be $78.65 m in FY, 2020
USD

Revenue (Q1, 2021)

20.9m

Gross profit (Q1, 2021)

7.4m

Gross profit margin (Q1, 2021), %

35.6%

Net income (Q1, 2021)

(12.4m)

EBIT (Q1, 2021)

(12.5m)

Market capitalization (15-Sept-2021)

939.6m

Closing stock price (15-Sept-2021)

21.4

Cash (31-Mar-2021)

137.1m

EV

810.7m
Personalis's current market capitalization is $939.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

9.4m37.8m65.2m78.6m

Revenue growth, %

302%

Cost of goods sold

11.7m26.0m43.1m58.5m

Gross profit

(2.3m)11.8m22.1m20.1m
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

4.2m14.1m15.8m17.2m19.2m19.5m19.8m20.9m

Cost of goods sold

4.1m10.1m9.9m11.5m15.1m14.8m14.5m13.5m

Gross profit

99.0k4.0m5.9m5.6m4.0m4.7m5.3m7.4m

Gross profit Margin, %

2%28%37%33%21%24%27%36%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

22.6m19.7m55.0m68.5m

Accounts Receivable

1.9m4.5m3.3m6.3m

Prepaid Expenses

808.0k1.9m3.4m5.4m

Current Assets

26.7m29.6m139.6m220.7m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

33.2m163.3m87.0m46.7m25.0m133.2m137.1m

Accounts Receivable

3.1m7.5m4.4m5.5m5.4m5.9m8.1m

Prepaid Expenses

3.7m1.9m4.0m3.4m3.0m5.4m5.6m

Current Assets

42.9m176.2m140.3m135.4m120.1m223.6m372.7m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(23.6m)(19.9m)(25.1m)(41.3m)

Depreciation and Amortization

1.2m3.1m4.7m5.8m

Accounts Payable

2.6m2.2m1.4m751.0k

Cash From Operating Activities

290.0k5.6m(18.1m)(42.7m)
Quarterly
USDQ1, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(5.4m)(11.6m)(18.4m)(9.1m)(18.4m)(27.9m)(12.4m)

Depreciation and Amortization

471.0k2.2m3.4m1.4m2.8m4.3m1.5m

Accounts Payable

(732.0k)(163.0k)474.0k2.4m(348.0k)(1.6m)(2.2m)

Cash From Operating Activities

723.0k(10.8m)(20.5m)(8.6m)(24.0m)(40.1m)(11.7m)
Show all financial metrics

Personalis Revenue Breakdown

Embed Graph

Personalis revenue breakdown by business segment: 50.8% from All other customers and 49.2% from VA MVP

Personalis Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Personalis Online and Social Media Presence

Embed Graph

Personalis News and Updates

Cancer genomics company Personalis expects to raise up to $107 million in IPO

Personalis Inc. disclosed Friday terms of its initial public offering, in which the cancer genomics company could raise up to $106.7 million, and be valued at up to about $456 million. The company said it was offering 6,666,667 shares in the IPO, which is expected to price between $14 and $16 a sha…

Personalis Blogs

Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth

Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth Content Import Sat, 09/18/2021 - 22:51 Personalis Receives New VA MVP Task Order and Record Quarterly Orders Fro…

Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference pamleonardo Thu, 08/26/2021 - 16:01 Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference August 26, 2021 This release is a backfill fr…

Personalis Announces Corporate Headquarters Expansion to Accelerate Growth in Laboratory Operations and Research & Development

MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 25, 2021-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will relocate both its corporate headquarters and the Personalis Clinical Laboratory from Menlo Park to 6600 Dumbarton Circle in Fremont

Personalis Reports Second Quarter 2021 Financial Results

MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 4, 2021-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021 . Second Quarter and Recent Highlights Record quarterly revenue of

Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 3, 2021-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6 th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021 .

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients

MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 2, 2021-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study " Prediction of immunotherapy response in melanoma through combined modeling of neoantigen
Show more

Personalis Frequently Asked Questions

  • When was Personalis founded?

    Personalis was founded in 2011.

  • Who are Personalis key executives?

    Personalis's key executives are John West, Richard Chen and Aaron Tachibana.

  • How many employees does Personalis have?

    Personalis has 147 employees.

  • What is Personalis revenue?

    Latest Personalis annual revenue is $78.6 m.

  • What is Personalis revenue per employee?

    Latest Personalis revenue per employee is $535 k.

  • Who are Personalis competitors?

    Competitors of Personalis include CBLPath, Complete Genomics and Accuray.

  • Where is Personalis headquarters?

    Personalis headquarters is located at 1330 O'Brien Dr, Menlo Park.

  • Where are Personalis offices?

    Personalis has offices in Menlo Park and West Wickham.

  • How many offices does Personalis have?

    Personalis has 2 offices.